Pathogenic mechanisms and experimental models of multiple sclerosis

References

• Hauser SL. Multiple lessons for multiple sclerosis. N Engl J Med. 2008; 359 17: 1838–1841.
   PubMed Web of Science ®Google Scholar
• Compston A. 2006. McAlpine's multiple sclerosis. Philadelphia: Churchill Livingstone Elsevier.
   Google Scholar
• Sotgiu S, Pugliatti M, Fois ML, Arru G, Sanna A, Sotgiu MA, Rosati G. Genes, environment, and susceptibility to multiple sclerosis. Neurobiol Dis. 2004; 17 2: 131–143.
   PubMed Web of Science ®Google Scholar
• Fugger L, Friese MA, Bell JI. From genes to function: The next challenge to understanding multiple sclerosis. Nat Rev Immunol. 2009; 9 6: 408–417.
   PubMed Web of Science ®Google Scholar
• Frohman EM, Racke MK, Raine CS. Multiple sclerosis—the plaque and its pathogenesis. N Engl J Med. 2006; 354 9: 942–955.
   PubMed Web of Science ®Google Scholar
• Geurts JJ, Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol. 2008; 7 9: 841–851.
   PubMed Web of Science ®Google Scholar
• Weiner HL. The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?. Ann Neurol. 2009; 65 3: 239–248.
   PubMed Web of Science ®Google Scholar
• Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: Lessons from failed and interrupted treatment trials. BioDrugs. 2002; 16 3: 183–200.
   PubMed Web of Science ®Google Scholar
• Clerico M, Contessa G, Durelli L. Interferon-beta1a for the treatment of multiple sclerosis. Expert Opin Biol Ther. 2007; 7 4: 535–542.
   PubMed Web of Science ®Google Scholar
• Arnon R, Aharoni R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci USA. 2004; 101 Suppl. 2: 14593–14598.
   PubMed Web of Science ®Google Scholar
• Vandenbark AA, Huan J, Agotsch M, La TD, Goelz S, Offner H, Lanker S, Bourdette D. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+ CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol. 2009; 215 1–2: 125–128.
   PubMed Web of Science ®Google Scholar
• Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial. Lancet. 2009; 374 9700: 1503–1511.
   PubMed Web of Science ®Google Scholar
• Haas J, Korporal M, Balint B, Fritzsching B, Schwarz A, Wildemann B. Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis. J Neuroimmunol. 2009; 216 1–2: 113–117.
   PubMed Web of Science ®Google Scholar
• Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol. 2004; 156 1–2: 3–9.
   PubMed Web of Science ®Google Scholar
• Warnke C, Meyer Zu HG, Hartung HP, Stuve O, Kieseier BC. Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2009; 5:333–340.
   PubMed Web of Science ®Google Scholar
• Linker RA, Kieseier BC, Gold R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci. 2008; 29 11: 558–565.
   PubMed Web of Science ®Google Scholar
• O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de VA, Pohlmann H, Kappos L. Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study. Neurology. 2009; 72 1: 73–79.
   PubMed Web of Science ®Google Scholar
• Sawicka E, Dubois G, Jarai G, Edwards M, Thomas M, Nicholls A, Albert R, Newson C, Brinkmann V, Walker C. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity. J Immunol. 2005; 175 12: 7973–7980.
   PubMed Web of Science ®Google Scholar
• Osborne R. Buzz around Campath proof-of-concept trial in MS. Nat Biotechnol. 2009; 27 1: 6–8.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK. Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N Engl J Med. 2008; 359 17: 1786–1801.
   PubMed Web of Science ®Google Scholar
• Cox AL, Thompson SA, Jones JL, Robertson VH, Hale G, Waldmann H, Compston DA, Coles AJ. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol. 2005; 35 11: 3332–3342.
   PubMed Web of Science ®Google Scholar
• Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, Frank JA, Wurfel J, Ohayon J, Waldmann TA, McFarland HF, Martin R. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA. 2004; 101 23: 8705–8708.
   PubMed Web of Science ®Google Scholar
• Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA. 2006; 103 15: 5941–5946.
   PubMed Web of Science ®Google Scholar
• Samijn JP, te Boekhorst PA, Mondria T, van Doorn PA, Flach HZ, van der Meche FG, Cornelissen J, Hop WC, Lowenberg B, Hintzen RQ. Intense T-cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psych. 2006; 77 1: 46–50.
   PubMed Web of Science ®Google Scholar
• Krishnan C, Kaplin AI, Brodsky RA, Drachman DB, Jones RJ, Pham DL, Richert ND, Pardo CA, Yousem DM, Hammond E, Quigg M, Trecker C, McArthur JC, Nath A, Greenberg BM, Calabresi PA, Kerr DA. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol. 2008; 65 8: 1044–1051.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med. 2008; 358 7: 676–688.
   PubMed Web of Science ®Google Scholar
• Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH. Rituximab in patients with PP multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009; 66 4: 460–471.
   PubMed Web of Science ®Google Scholar
• Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing–remitting multiple sclerosis: A phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008; 7 9: 796–804.
   PubMed Web of Science ®Google Scholar
• Martin R. Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis. Lancet Neurol. 2008; 7 9: 765–766.
   PubMed Web of Science ®Google Scholar
• Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med. 2008; 205 7: 1535–1541.
   PubMed Web of Science ®Google Scholar
• Steinman L, Zamvil SS. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 2005; 26 11: 565–571.
   PubMed Web of Science ®Google Scholar
• Lincoln MR, Montpetit A, Cader MZ, Saarela J, Dyment DA, Tiislar M, Ferretti V, Tienari PJ, Sadovnick AD, Peltonen L, Ebers GC, Hudson TJ. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet. 2005; 37 10: 1108–1112.
   PubMed Web of Science ®Google Scholar
• Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, de Bakker PI, Gabriel SB, Mirel DB, Ivinson AJ, Pericak-Vance MA, Gregory SG, Rioux JD, McCauley JL, Haines JL, Barcellos LF, Cree B, Oksenberg JR, Hauser SL. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007; 357 9: 851–862.
   PubMed Web of Science ®Google Scholar
• Weber F, Fontaine B, Cournu-Rebeix I, Kroner A, Knop M, Lutz S, Muller-Sarnowski F, Uhr M, Bettecken T, Kohli M, Ripke S, Ising M, Rieckmann P, Brassat D, Semana G, Babron MC, Mrejen S, Gout C, Lyon-Caen O, Yaouanq J, Edan G, Clanet M, Holsboer F, Clerget-Darpoux F, Muller-Myhsok B. IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun. 2008; 9 3: 259–263.
   PubMed Web of Science ®Google Scholar
• Lowe CE, Cooper JD, Brusko T, Walker NM, Smyth DJ, Bailey R, Bourget K, Plagnol V, Field S, Atkinson M, Clayton DG, Wicker LS, Todd JA. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet. 2007; 39 9: 1074–1082.
   PubMed Web of Science ®Google Scholar
• Anonymous. The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes Immun. 2009; 10 1: 11–14[].
   PubMed Web of Science ®Google Scholar
• Hafler JP, Maier LM, Cooper JD, Plagnol V, Hinks A, Simmonds MJ, Stevens HE, Walker NM, Healy B, Howson JM, Maisuria M, Duley S, Coleman G, Gough SC, Worthington J, Kuchroo VK, Wicker LS, Todd JA. CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun. 2009; 10 1: 5–10.
   PubMed Web of Science ®Google Scholar
• Dardalhon V, Schubart AS, Reddy J, Meyers JH, Monney L, Sabatos CA, Ahuja R, Nguyen K, Freeman GJ, Greenfield EA, Sobel RA, Kuchroo VK. CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J Immunol. 2005; 175 3: 1558–1565.
   PubMed Web of Science ®Google Scholar
• Zoledziewska M, Costa G, Pitzalis M, Cocco E, Melis C, Moi L, Zavattari P, Murru R, Lampis R, Morelli L, Poddie F, Frongia P, Pusceddu P, Bajorek M, Marras A, Satta AM, Chessa A, Pugliatti M, Sotgiu S, Whalen MB, Rosati G, Cucca F, Marrosu MG. Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia. Genes Immun. 2009; 10 1: 15–17.
   PubMed Web of Science ®Google Scholar
• Aulchenko YS, Hoppenbrouwers IA, Ramagopalan SV, Broer L, Jafari N, Hillert J, Link J, Lundstrom W, Greiner E, Dessa SA, Goossens D, Van BC, Del-Favero J, Ebers GC, Oostra BA, van Duijn CM, Hintzen RQ. Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat Genet. 2008; 40 12: 1402–1403.
   PubMed Web of Science ®Google Scholar
• Ban M, Goris A, Lorentzen AR, Baker A, Mihalova T, Ingram G, Booth DR, Heard RN, Stewart GJ, Bogaert E, Dubois B, Harbo HF, Celius EG, Spurkland A, Strange R, Hawkins C, Robertson NP, Dudbridge F, Wason J, De Jager PL, Hafler D, Rioux JD, Ivinson AJ, McCauley JL, Pericak-Vance M, Oksenberg JR, Hauser SL, Sexton D, Haines J, Sawcer S, Compston A. Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur J Hum Genet. 2009; 17 10: 1309–1313.
   PubMed Web of Science ®Google Scholar
• De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT, Piccio L, Raychaudhuri S, Tran D, Aubin C, Briskin R, Romano S, Baranzini SE, McCauley JL, Pericak-Vance MA, Haines JL, Gibson RA, Naeglin Y, Uitdehaag B, Matthews PM, Kappos L, Polman C, McArdle WL, Strachan DP, Evans D, Cross AH, Daly MJ, Compston A, Sawcer SJ, Weiner HL, Hauser SL, Hafler DA, Oksenberg JR. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009; 41 7: 776–782.
   PubMed Web of Science ®Google Scholar
• Caillier S, Barcellos LF, Baranzini SE, Swerdlin A, Lincoln RR, Steinman L, Martin E, Haines JL, Pericak-Vance M, Hauser SL, Oksenberg JR. Osteopontin polymorphisms and disease course in multiple sclerosis. Genes Immun. 2003; 4 4: 312–315.
   PubMed Web of Science ®Google Scholar
• Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De JP, Baecher-Allan C. Multiple sclerosis. Immunol Rev. 2005; 204:208–231.
   PubMed Web of Science ®Google Scholar
• Ransohoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol. 2003; 3 7: 569–581.
   PubMed Web of Science ®Google Scholar
• Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002; 8 5: 500–508.
   PubMed Web of Science ®Google Scholar
• Liu X, Lee YS, Yu CR, Egwuagu CE. Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases. J Immunol. 2008; 180 9: 6070–6076.
   PubMed Web of Science ®Google Scholar
• Haak S, Croxford AL, Kreymborg K, Heppner FL, Pouly S, Becher B, Waisman A. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Invest. 2009; 119 1: 61–69.
   PubMed Web of Science ®Google Scholar
• O'Connor RA, Prendergast CT, Sabatos CA, Lau CW, Leech MD, Wraith DC, Anderton SM. Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J Immunol. 2008; 181 6: 3750–3754.
   PubMed Web of Science ®Google Scholar
• Stromnes IM, Cerretti LM, Liggitt D, Harris RA, Goverman JM. Differential regulation of central nervous system autoimmunity by Th1 and Th17 cells. Nat Med. 2008; 14 3: 337–342.
   PubMed Web of Science ®Google Scholar
• Eikelenboom MJ, Killestein J, Izeboud T, Kalkers NF, van Lier RA, Barkhof F, Uitdehaag BM, Polman CH. Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis. J Neuroimmunol. 2002; 133 1–2: 225–232.
   PubMed Web of Science ®Google Scholar
• Blink SE, Miller SD. The contribution of gammadelta T cells to the pathogenesis of EAE and MS. Curr Mol Med. 2009; 9 1: 15–22.
   PubMed Web of Science ®Google Scholar
• Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity. 2009; 31 2: 331–341.
   PubMed Web of Science ®Google Scholar
• Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F. B cells and multiple sclerosis. Lancet Neurol. 2008; 7 9: 852–858.
   PubMed Web of Science ®Google Scholar
• Heppner FL, Greter M, Marino D, Falsig J, Raivich G, Hovelmeyer N, Waisman A, Rulicke T, Prinz M, Priller J, Becher B, Aguzzi A. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med. 2005; 11 2: 146–152.
   PubMed Web of Science ®Google Scholar
• Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, Laufer T, Noelle RJ, Becher B. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med. 2005; 11 3: 328–334.
   PubMed Web of Science ®Google Scholar
• Bailey-Bucktrout SL, Caulkins SC, Goings G, Fischer JA, Dzionek A, Miller SD. Cutting edge: Central nervous system plasmacytoid dendritic cells regulate the severity of relapsing experimental autoimmune encephalomyelitis. J Immunol. 2008; 180 10: 6457–6461.
   PubMed Web of Science ®Google Scholar
• Bayas A, Stasiolek M, Kruse N, Toyka KV, Selmaj K, Gold R. Altered innate immune response of plasmacytoid dendritic cells in multiple sclerosis. Clin Exp Immunol. 2009; 157 3: 332–342.
   PubMed Web of Science ®Google Scholar
• Bailey SL, Schreiner B, McMahon EJ, Miller SD. CNS myeloid DCs presenting endogenous myelin peptides ‘preferentially’ polarize CD4+ Th-17 cells in relapsing EAE. Nat Immunol. 2007; 8 2: 172–180.
   PubMed Web of Science ®Google Scholar
• Deshpande P, King IL, Segal BM. Cutting edge: CNS CD11c+ cells from mice with encephalomyelitis polarize Th17 cells and support CD25+CD4+ T cell-mediated immunosuppression, suggesting dual roles in the disease process. J Immunol. 2007; 178 11: 6695–6699.
   PubMed Web of Science ®Google Scholar
• Becher B, Durell BG, Miga AV, Hickey WF, Noelle RJ. The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. J Exp Med. 2001; 193 8: 967–974.
   PubMed Web of Science ®Google Scholar
• Weber F, Meinl E, Aloisi F, Nevinny-Stickel C, Albert E, Wekerle H, Hohlfeld R. Human astrocytes are only partially competent antigen presenting cells. Possible implications for lesion development in multiple sclerosis. Brain. 1994; 117 Pt 1: 59–69.
   PubMed Web of Science ®Google Scholar
• Stuve O, Youssef S, Slavin AJ, King CL, Patarroyo JC, Hirschberg DL, Brickey WJ, Soos JM, Piskurich JF, Chapman HA, Zamvil SS. The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease. J Immunol. 2002; 169 12: 6720–6732.
   PubMed Web of Science ®Google Scholar
• Xiao BG, Diab A, Zhu J, van der MP, Link H. Astrocytes induce hyporesponses of myelin basic protein-reactive T- and B-cell function. J Neuroimmunol. 1998; 89 1–2: 113–121.
   PubMed Web of Science ®Google Scholar
• Emerson MR, Gallagher RJ, Marquis JG, LeVine SM. Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design. Comp Med. 2009; 59 2: 112–128.
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy G, Wekerle H. EAE: An immunologist's magic eye. Eur J Immunol. 2009; 39 8: 2031–2035.
   PubMed Web of Science ®Google Scholar
• Zhao ML, Fritz RB. Acute and relapsing experimental autoimmune encephalomyelitis in IL-4- and α/β T-cell-deficient C57BL/6 mice. J Neuroimmunol. 1998; 87 1–2: 171–178.
   PubMed Web of Science ®Google Scholar
• Jager A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK. Th1, Th17, and Th9-effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol. 2009; 183 11: 7169–7177.
   PubMed Web of Science ®Google Scholar
• Pollinger B, Krishnamoorthy G, Berer K, Lassmann H, Bosl MR, Dunn R, Domingues HS, Holz A, Kurschus FC, Wekerle H. Spontaneous relapsing–remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med. 2009; 206 6: 1303–1316.
   PubMed Web of Science ®Google Scholar
• Bahbouhi B, Berthelot L, Pettre S, Michel L, Wiertlewski S, Weksler B, Romero IA, Miller F, Couraud PO, Brouard S, Laplaud DA, Soulillou JP. Peripheral blood CD4+ T lymphocytes from multiple sclerosis patients are characterized by higher PSGL-1 expression and transmigration capacity across a human blood–brain barrier-derived endothelial cell line. J Leukoc Biol. 2009; 86 5: 1049–1063.
   PubMed Web of Science ®Google Scholar
• Battistini L, Piccio L, Rossi B, Bach S, Galgani S, Gasperini C, Ottoboni L, Ciabini D, Caramia MD, Bernardi G, Laudanna C, Scarpini E, McEver RP, Butcher EC, Borsellino G, Constantin G. CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: A critical role for P-selectin glycoprotein ligand-1. Blood. 2003; 101 12: 4775–4782.
   PubMed Web of Science ®Google Scholar
• Steinman L. A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol. 2009; 9 6: 440–447.
   PubMed Web of Science ®Google Scholar
• Vogt MH, Lopatinskaya L, Smits M, Polman CH, Nagelkerken L. Elevated osteopontin levels in active relapsing–remitting multiple sclerosis. Ann Neurol. 2003; 53 6: 819–822.
   PubMed Web of Science ®Google Scholar
• Drulovic J, Savic E, Pekmezovic T, Mesaros S, Stojsavljevic N, Dujmovic-Basuroski I, Kostic J, Vasic V, Mostarica SM, Popadic D. Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: Does baseline T-bet mRNA predict the response to interferon-beta treatment?. J Neuroimmunol. 2009; 215 1–2: 90–95.
   PubMed Web of Science ®Google Scholar
• Whitaker JN. The presence of immunoreactive myelin basic protein peptide in urine of persons with multiple sclerosis. Ann Neurol. 1987; 22 5: 648–655.
   PubMed Web of Science ®Google Scholar